Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
35.51
-0.37 (-1.03%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Simulations Plus Revenue
Simulations Plus had revenue of $22.43M in the quarter ending February 28, 2025, with 22.55% growth. This brings the company's revenue in the last twelve months to $78.56M, up 21.49% year-over-year. In the fiscal year ending August 31, 2024, Simulations Plus had annual revenue of $70.01M with 17.52% growth.
Revenue (ttm)
$78.56M
Revenue Growth
+21.49%
P/S Ratio
9.06
Revenue / Employee
$318,073
Employees
247
Market Cap
713.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
Aug 31, 2019 | Pro | Pro | Pro |
Aug 31, 2018 | Pro | Pro | Pro |
Aug 31, 2017 | Pro | Pro | Pro |
Aug 31, 2016 | Pro | Pro | Pro |
Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
SLP News
- 6 days ago - Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies - Business Wire
- 11 days ago - Simulations Plus: Benefiting From FDA Modernization And AI - Seeking Alpha
- 16 days ago - What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
- 23 days ago - Simulations Plus: I See Promising Growth, But I'm Staying Neutral - Seeking Alpha
- 24 days ago - Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results - Business Wire
- 4 weeks ago - Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga
- 5 weeks ago - Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date - Business Wire